16 April 2024
The Law Debenture Corporation p.l.c. (the "Corporation")
Notification of a Transaction by a Person Discharging Managerial Responsibility ("PDMR") and a Person Closely Associated ("PCA") with the PDMR
The Corporation was informed of the following transaction on 15 April 2024. The relevant notification set out below is provided in accordance with the requirements of Article 19 of the UK's retained EU law version of the Market Abuse Regulation (596/2014).
| 1
| Details of the PDMR and the PCA | ||||
| a) | Name of PDMR Name of PCA | Parwinder Purewal Sally Cosgrove | |||
| 2
| Reason for the notification | ||||
| a) | Position/status of PDMR Position/status of PCA | Non-Executive Director PCA with Parwinder Purewal | |||
| b) | Initial notification /Amendment | Initial notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | The Law Debenture Corporation p.l.c. | |||
| b) | LEI | 2138006E39QX7XV6PP21 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5p each | |||
| | | ||||
| Identification code |
| ||||
| | | ||||
| b)
| Nature of the transaction | Joint acquisition of shares by dividend reinvestment. | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Price(s) | Volume(s) | | |
| | | 8.158164 pence per share | 292 | | |
| | | | | | |
| d)
| Aggregated information | | |||
| | | ||||
| - Aggregated volume | 292 | ||||
| | | ||||
| - Price | £2382.18 | ||||
| | | ||||
| e) | Date of the transaction | 15 April 2024 | |||
| f) | Place of the transaction | London Stock Exchange | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
